Rapport Therapeutics, Inc. (RAPP) — 10-Q Filings

10-Q Filings (5)

• RAPP's Net Loss Widens Amid Soaring R&D, Cash Reserves Boosted by Offering — Nov 6, 2025 Risk: high
  Rapport Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $77.72 million, compared to $58.33
• Rapport's Q2 Losses Widen Amid R&D Surge — Aug 7, 2025 Risk: high
  Rapport Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The net loss for the
• Rapport Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Rapport Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and operational activities. Key fina
• Rapport Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Rapport Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, located at 1325 Boylston Street, Suite 401, Boston, MA, reporte
• Rapport Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Rapport Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and operations, including details

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX